Acurx Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ACXP Nasdaq 8731 https://www.acurxpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Acurx Pharmaceuticals Inc

Acurx Pharmaceuticals, Inc. Reports First Quarter 2022 Results and Provides Business Update - May 11th, 2022 11:01 am
Acurx Pharmaceuticals, Inc. to Discuss 2022 First Quarter Financial Results on May 11, 2022 Conference Call and Provide Business Update - Apr 29th, 2022 12:01 pm
Acurx Pharmaceuticals (NASDAQ:ACXP) Is In A Good Position To Deliver On Growth Plans - Mar 24th, 2022 7:23 pm
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update - Mar 17th, 2022 11:01 am
Acurx Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28-30, 2022 from 9:00 a.m. - 5:00 p.m. EDT - Mar 16th, 2022 12:01 pm
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update - Mar 7th, 2022 1:01 pm
Acurx Announces Publication of Positive Phase 2a Clinical Trial Results of Ibezapolstat for CDI in Clinical Infectious Diseases - Feb 7th, 2022 1:01 pm
Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI) - Dec 6th, 2021 1:01 pm
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2021 Results and Provides Business Update - Nov 12th, 2021 11:01 pm
Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference - Nov 8th, 2021 1:01 pm
Acurx Pharmaceuticals to Discuss 2021 Third Quarter Financial Results on November 15, 2021 Conference Call and Provide Business Update - Oct 27th, 2021 12:01 pm
Acurx Presents Positive Ibezapolstat Microbiome Data from Its Phase 2a Trial at IDWeek - Oct 4th, 2021 1:00 pm
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021 - Sep 30th, 2021 12:00 pm
Acurx Pharmaceuticals to Participate in the A.G.P. Biotech and Specialty Pharma Conference October 13, 2021 - Sep 29th, 2021 12:00 pm
Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI in a Scientific Poster Presentation at IDWeek 2021 Conference - Sep 27th, 2021 12:00 pm
We Think Acurx Pharmaceuticals (NASDAQ:ACXP) Can Easily Afford To Drive Business Growth - Sep 25th, 2021 12:02 pm
CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts - Sep 13th, 2021 12:03 pm
Acurx Pharmaceuticals to Join the Russell Microcap Index® - Sep 2nd, 2021 12:00 pm
Acurx Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 - Aug 31st, 2021 12:00 pm
CEO Presenting on the Emerging Growth Conference on August 18. Register Now - Aug 17th, 2021 11:00 am